merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>significant safety risks (brain swelling and bleeding)</answer>
<question_number>2</question_number>
<answer>may discourage patient participation in other trials, slowing progress</answer>
<question_number>3</question_number>
<answer>no correlation between amyloid plaque removal and clinical response in individuals</answer>
<question_number>4</question_number>
<answer>could heighten concerns about Kisunlaâ€™s safety</answer>
<question_number>5</question_number>
<answer>expectation patients can stop after amyloid clearance, reducing overall cost</answer>
<question_number>6</question_number>
<answer>may discourage patients from enrolling in other, potentially better, trials</answer>
<question_number>7</question_number>
<answer>monthly infusions and ability to stop after plaque clearance</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>patients with intermediate tau levels declined more slowly than those with high tau</answer>